News
French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal ...
Doctors highlighted the need for a comprehensive national strategy to tackle AML and the need for recognising the ...
During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic ...
TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases ...
TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in ...
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – ...
GlobalData on MSN2d
Auron doses first subject in AUTX-703 trial for haematologic malignanciesThe trial targets individuals with relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes.
TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in hig ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...
INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback